Skip to main content

Table 2 Patient characteristics according to CPG or LSD genes carrier status

From: Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

Variable

CPG carriera

LSD gene carriera

Non-carrier

P-value

 

n = 15

n = 32

n = 371

 

Age, years, mean ± SD

60.3 ± 7.2

61.7 ± 11.5

65.3 ± 9.54

0.025

Sex

 

 Male

9 (2.2)

22 (5.3)

212 (50.7)

0.438

 Female

6 (1.4)

10 (2.4)

159 (38.0)

 

 BMI, kg/m2, mean ± SD

23.0 ± 2.8

22.3 ± 2.6

22.8 ± 3.0

0.628

DM, no. (%)

 

 Yes

5 (1.2)

14 (3.3)

127 (30.4)

0.551

 No

10 (2.4)

18 (4.3)

244 (58.4)

 

Smoking, no. (%)

0.597

 Yes

3 (0.7)

11 (2.6)

108 (25.8)

 

 No

12 (2.9)

21 (5.0)

263 (62.9)

 

Alcohol, no. (%)

0.809

 Yes

4 (1.0)

10 (2.4)

126 (30.1)

 

 No

11 (2.6)

22 (5.3)

245 (58.6)

 

 CEA, ng/mL, mean ± SD

9.7 ± 25.5

4.0 ± 6.5

9.9 ± 55.2

0.872

 CA 19–9, U/mL, mean ± SD

555.0 ± 1136.3

4092.3 ± 8559.6

2677.3 ± 11,499.8

0.588

AJCC 8th stage, no. (%)

0.840

 I

4 (1.0)

8 (1.9)

66 (15.8)

 

 II

4 (1.0)

11 (2.6)

108 (25.8)

 

 III

4 (1.0)

7 (1.7)

101 (24.2)

 

 IV

3 (0.7)

6 (1.4)

96 (23.0)

 
  1. CPG cancer predisposition genes, LSD lysosomal storage disease, SD standard deviation, BMI body mass index, DM diabetes mellitus, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, AJCC The American Joint Committee on Cancer
  2. aTwo patients who were carriers of both the CPG and LSD genes were classified as CPG carriers